

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

|                       |                                    |
|-----------------------|------------------------------------|
| <b>Name of entity</b> | <b>ZELIRA THERAPEUTICS LIMITED</b> |
| <b>ABN</b>            | 27 103 782 378                     |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |                  |
|----------------------------|------------------|
| <b>Name of Director</b>    | Richard Hopkins  |
| <b>Date of last notice</b> | 23 December 2019 |

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |   |
|---|---|
| <b>Direct or indirect interest</b>  | <b>Indirect</b>   |
| <b>Nature of indirect interest (including registered holder)</b><br><small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | i. Vanhop Pty Ltd <Vanhop Super Fund A/C> - Director and beneficiary<br><br>ii. Mr Richard Miles Hopkins & Ms Maya Maureen vanden Dreisen <Jesam A/C> - Beneficiary   |
| <b>Date of change</b>   | 11 August 2020  |
| <b>No. of securities held prior to change</b>   | i. 700,000 ordinary shares<br>i. 3,125,000 Class A performance rights<br>i. 3,125,000 Class B performance rights<br>ii. 3,125,000 Class A performance rights<br>ii. 3,125,000 Class B performance rights<br>ii. 5,000,000 unlisted options with an exercise price of \$0.10 each and expire on 19 February 2022<br>ii. 5,000,000 unlisted options with an exercise price of \$0.15 each and expire on 19 February 2022<br>ii. 5,000,000 unlisted options with an exercise price of \$0.20 each and expire on 19 February 2022<br>ii. 5,000,000 unlisted options with an exercise price of \$0.28 each, vesting on 16 October 2020 and expire on 19 February 2022<br>ii. 5,000,000 unlisted options with an exercise price of \$0.30 each, vesting on 16 October 2020 and expire on 19 February 2022 |

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

|   |  |
|---|--|
| <b>Class</b>  | Ordinary Shares  |
| <b>Number acquired</b>  | 1,000,000  |
| <b>Number disposed</b>  | N/A  |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and estimated valuation   | \$0.05 per share   |
| <b>No. of securities held after change</b>  | <ul style="list-style-type: none"> <li>i. 1,700,000 ordinary shares</li> <li>i. 3,125,000 Class A performance rights</li> <li>i. 3,125,000 Class B performance rights</li> <li>ii. 3,125,000 Class A performance rights</li> <li>ii. 3,125,000 Class B performance rights</li> <li>ii. 5,000,000 unlisted options with an exercise price of \$0.10 each, vesting immediately and expire on 19 February 2022</li> <li>ii. 5,000,000 unlisted options with an exercise price of \$0.15 each, subject to vesting conditions vesting on 16 October 2019 and expire on 19 February 2022</li> <li>ii. 5,000,000 unlisted options with an exercise price of \$0.20 each, subject to vesting conditions vesting on 16 October 2019 and expire on 19 February 2022</li> <li>ii. 5,000,000 unlisted options with an exercise price of \$0.28 each, vesting on 16 October 2020 and expire on 19 February 2022</li> <li>ii. 5,000,000 unlisted options with an exercise price of \$0.30 each, vesting on 16 October 2020 and expire on 19 February 2022</li> </ul> |
| <b>Nature of change</b><br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Participation in Placement as approved by shareholders on 21 July 2020.  |

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

|  |  |
|--|--|
| <b>Detail of contract</b>  |  |
| <b>Nature of interest</b>  |  |
| <b>Name of registered holder (if issued securities)</b>  |  |
| <b>Date of change</b>  |  |
| <b>No. and class of securities to which interest related prior to change</b><br>Note: Details are only required for a contract in relation to which the interest has changed |  |
| <b>Interest acquired</b>   |  |
| <b>Interest disposed</b>   |  |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and an estimated valuation   |  |
| <b>Interest after change</b>   |  |

+ See chapter 19 for defined terms.

**Part 3 – <sup>+</sup>Closed period**

|   |     |
|---|-----|
| Were the interests in the securities or contracts detailed above traded during a <sup>+</sup> closed period where prior written clearance was required? | No  |
| If so, was prior written clearance provided to allow the trade to proceed during this period?   | N/A |
| If prior written clearance was provided, on what date was this provided?  | N/A |

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

|                       |                                    |
|-----------------------|------------------------------------|
| <b>Name of entity</b> | <b>ZELIRA THERAPEUTICS LIMITED</b> |
| <b>ABN</b>            | 27 103 782 378                     |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |                 |
|----------------------------|-----------------|
| <b>Name of Director</b>    | Oludare Odumosu |
| <b>Date of last notice</b> | 2 January 2020  |

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |  |
|---|--|
| <b>Direct or indirect interest</b>  | Direct   |
| <b>Nature of indirect interest (including registered holder)</b><br><small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> |  |
| <b>Date of change</b>   | 11 August 2020   |
| <b>No. of securities held prior to change</b>   | A. 5,500,655 ordinary shares<br>B. 17,558,328 Class A performance rights<br>C. 17,558,328 Class B performance rights   |
| <b>Class</b>  | D. Unquoted options exercisable at \$0.10 on or before 11 August 2023.<br>E. Unquoted options exercisable at \$0.15 on or before 11 August 2023 and subject to vesting conditions.<br>F. Unquoted options exercisable at \$0.20 on or before 11 August 2023 and subject to vesting conditions.<br>G. Unquoted options exercisable at \$0.28 on or before 11 August 2023 and subject to vesting conditions.<br>H. Unquoted options exercisable at \$0.30 on or before 11 August 2023 and subject to vesting conditions. |

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

|  |  |
|--|--|
| <b>Number acquired</b>   | D. 5,000,000<br>E. 5,000,000<br>F. 5,000,000<br>G. 5,000,000<br>H. 5,000,000   |
| <b>Number disposed</b>   |  |
| <b>Value/Consideration</b><br><small>Note: If consideration is non-cash, provide details and estimated valuation</small>   | Nil consideration - issued as part director services – refer to the Notice of the General Meeting held on 17 June 2020 for further details   |
| <b>No. of securities held after change</b>   | A. 5,500,655 ordinary shares<br>B. 17,558,328 Class A performance rights<br>C. 17,558,328 Class B performance rights<br>D. 5,000,000 Unquoted options exercisable at \$0.10 on or before 11 August 2023.<br>E. 5,000,000 Unquoted options exercisable at \$0.15 on or before 11 August 2023 and subject to vesting conditions.<br>F. 5,000,000 Unquoted options exercisable at \$0.20 on or before 11 August 2023 and subject to vesting conditions.<br>G. 5,000,000 Unquoted options exercisable at \$0.28 on or before 11 August 2023 and subject to vesting conditions.<br>H. 5,000,000 Unquoted options exercisable at \$0.30 on or before 11 August 2023 and subject to vesting conditions. |
| <b>Nature of change</b><br><small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small> | As approved by shareholders on 21 July 2020  |

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

|   |  |
|---|--|
| <b>Detail of contract</b>   |  |
| <b>Nature of interest</b>   |  |
| <b>Name of registered holder (if issued securities)</b>   |  |
| <b>Date of change</b>   |  |
| <b>No. and class of securities to which interest related prior to change</b><br><small>Note: Details are only required for a contract in relation to which the interest has changed</small> |  |
| <b>Interest acquired</b>  |  |
| <b>Interest disposed</b>  |  |

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

|   |  |
|---|--|
| <b>Value/Consideration</b><br><small>Note: If consideration is non-cash, provide details and an estimated valuation</small> |  |
| <b>Interest after change</b>  |  |

**Part 3 – <sup>+</sup>Closed period**

|   |     |
|---|-----|
| <b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b> | N/A |
| <b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>  | N/A |
| <b>If prior written clearance was provided, on what date was this provided?</b>   | N/A |

---

<sup>+</sup> See chapter 19 for defined terms.